One‑year graft failure‑free survival reaches 90% in crossmatch‑positive transplants

Combination shows strong PFS and OS gains in MET‑overexpressing EGFRm disease

SARON trial shows 56% improvement over standard treatment

Early responses suggest restored sensitivity to anti‑PD‑1 therapy

First-in-class therapy offers functional cure potential

First SC option offers new flexibility for patients

Second-line authorisation expands immunotherapy options

Results support advancement into phase 2 trials

Agreement enables procurement in over 50 countries